PORCELLI, LETIZIA
 Distribuzione geografica
Continente #
NA - Nord America 1.425
EU - Europa 293
AS - Asia 85
OC - Oceania 3
SA - Sud America 1
Totale 1.807
Nazione #
US - Stati Uniti d'America 1.422
SE - Svezia 115
IT - Italia 65
CN - Cina 64
GB - Regno Unito 31
DE - Germania 23
BE - Belgio 17
FR - Francia 16
FI - Finlandia 10
VN - Vietnam 8
IN - India 6
NL - Olanda 4
RU - Federazione Russa 4
AU - Australia 3
CA - Canada 3
ID - Indonesia 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
BG - Bulgaria 1
BY - Bielorussia 1
IE - Irlanda 1
IR - Iran 1
JP - Giappone 1
KZ - Kazakistan 1
MD - Moldavia 1
MT - Malta 1
RS - Serbia 1
SG - Singapore 1
TR - Turchia 1
Totale 1.807
Città #
Fairfield 221
Woodbridge 168
Chandler 166
Ashburn 119
Seattle 92
Houston 91
Nyköping 91
Cambridge 87
Wilmington 67
Ann Arbor 49
Bari 33
New York 28
Beijing 26
Lawrence 26
Roxbury 25
Brussels 17
Brooklyn 16
Nanjing 12
Des Moines 11
San Diego 10
Dearborn 9
Inglewood 8
Paris 8
Dong Ket 6
London 6
Monmouth Junction 6
Miami 5
Falls Church 4
Helsinki 4
Napoli 4
Pune 4
Washington 4
Changsha 3
Detroit 3
Jiaxing 3
Kunming 3
Leawood 3
Marseille 3
Nanchang 3
Princeton 3
Shenyang 3
Triggiano 3
Amsterdam 2
Bitonto 2
Boardman 2
Casoria 2
Dalmine 2
Groningen 2
Hanoi 2
Hefei 2
Los Angeles 2
Melbourne 2
Milan 2
Norwalk 2
Prescot 2
Reggio Emilia 2
San Mateo 2
Tianjin 2
Toronto 2
Acton 1
Almaty 1
Ardabil 1
Atlanta 1
Augusta 1
Belgrade 1
Brindisi 1
Canberra 1
Chisinau 1
Cormeilles-en-Parisis 1
Dublin 1
Esslingen am Neckar 1
Ferrara 1
Grafing 1
Guangzhou 1
Hangzhou 1
Hounslow 1
Il-Madliena 1
Jacksonville 1
Jinan 1
Kansas City 1
Lanzhou 1
Markham 1
Minsk 1
Mumbai 1
New Bedfont 1
Oklahoma City 1
Phoenix 1
Rome 1
San Jose 1
Sankt Augustin 1
Sofia 1
Tamm 1
Tappahannock 1
Tirana 1
Tokyo 1
Vienna 1
Wuhan 1
Zhengzhou 1
Totale 1.526
Nome #
New insight into the role of metabolic reprogramming in melanoma cells harboring braf mutations. 128
Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma 116
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors 106
null 106
Drug delivery nanovectors based on SPIONS for targeted therapy of hepatocellular carcinoma 104
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 103
CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer 90
Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives 88
null 86
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 82
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 80
Synthetic lethality to overcome cancer drug resistance 76
p53 as the main traffic controller of the cell signaling network 75
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 75
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 72
null 71
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 61
Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors 52
Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer 48
Tomatine displays antitumor potential in in vitro models of metastatic melanoma 41
Hydroxy-propil-β-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models 37
The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study 34
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination 29
The role of non-coding RNAs as prognostic factor, predictor of drug response or resistance and pharmacological targets, in the cutaneous squamous cell carcinoma 29
Long non‐coding rna landscape in prostate cancer molecular subtypes: A feature selection approach 29
Microfluidic-assisted preparation of targeted ph-responsive polymeric micelles improves gemcitabine effectiveness in pdac: In vitro insights 29
Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells 27
Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab 14
BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy 13
Gene Expression Comparison between Alcohol-Exposed Versus Not Exposed Pancreatic Ductal Adenocarcinoma Patients Reveals a Peculiar TGFβ-Related Phenotype: An Exploratory Analysis 8
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma 3
Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers 3
Totale 1.915
Categoria #
all - tutte 8.466
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.466


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201959 0 0 0 0 0 0 0 0 0 0 31 28
2019/2020480 45 12 12 31 65 43 47 62 76 34 36 17
2020/2021358 16 28 26 20 30 29 42 20 35 48 44 20
2021/2022272 9 31 3 3 21 30 10 15 25 22 31 72
2022/2023424 40 72 28 41 37 55 11 44 67 3 11 15
2023/2024160 17 23 14 11 27 46 2 8 6 6 0 0
Totale 1.915